SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
HEP_25734_sm_SuppFig1.tif533KSupporting Information Appendix Figure 1. Indirect comparison meta-analysis of published peginterferon alfa (2a or 2b) and ribavirin RCTs in the treatment of untreated genotype 1 chronic hepatitis C patients. The pooled estimates by random effect model of sustained virologic response to peginterferon alfa 2a or 2b in combination with ribavirin were 46.3% (95% CI 42%-51%) and 45.3% (95% CI 39%-53%), respectively.
HEP_25734_sm_SuppFig2A.tif141KSupporting Information Appendix Figure 2. Dual therapy (DT) and 5 competing strategies proposed. (2A) DT: In accordance with the European Association for the Study of the Liver Clinical Practice Guidelines (17), patients received PEG-IFN plus ribavirin (PR) therapy for short (24 weeks), standard (48 weeks), or prolonged (72 weeks) treatment duration, according to pre-treatment HCV RNA viral load and on-treatment response. RVR= rapid virologic response; EVR= early virologic response; NR= no response; LVL= low viral load (≤400.000 UI/ml); HVL= high viral load (> 400.000 UI/ml).
HEP_25734_sm_SuppFig2B.tif92KSupporting Information Appendix Figure 2. Dual therapy (DT) and 5 competing strategies proposed. (2B) Boceprevir response-guided therapy (BOC-RGT): After 4 weeks of PEG-IFN and RBV (PR lead-in period), patients whose HCV RNA level at weeks 8 and 24 was undetectable, defined as extended RVR (eRVR), received triple therapy (PR+BOC) for an additional 24 weeks, while patients with detectable HCV RNA at week 4 but undetectable at week 24, defined as no extended RVR (no eRVR), received triple therapy (PR+BOC) for an additional 8 weeks, continuing PR only through week 48, according to analyses by the FDA and EMEA (18,19).
HEP_25734_sm_SuppFig2C.tif39KSupporting Information Appendix Figure 2. Dual therapy (DT) and 5 competing strategies proposed. (2C) Boceprevir IL28B genotype-guided strategy (BOC-IL28B): IL28B C/C patients were treated with DT, while IL28B C/T or T/T patients received boceprevir response-guided therapy. IL28B C/C patients treated with DT, and who did not achieved SVR, were retreated with 4 week PR followed by 44 weeks of BOC in combination with PR according to RESPOND-2 RCT (20).
HEP_25734_sm_SuppFig2D.tif27KSupporting Information Appendix Figure 2. Dual therapy (DT) and 5 competing strategies proposed. (2D) Boceprevir RVR-guided strategy (BOC-RVR): All patients started therapy with PEG-IFN and ribavirin for 4 weeks (PR lead-in period), maintaining dual therapy (DT) if rapid virologic response (RVR) was achieved, and adding boceprevir according to BOC-RGT strategy if RVR was not achieved (no RVR). RVR patients treated with DT, and who did not achieved SVR, were retreated with 4 week PR followed by 44 weeks of BOC in combination with PR according to RESPOND-2 RCT (20).
HEP_25734_sm_SuppFig2E.tif89KSupporting Information Appendix Figure 2. Dual therapy (DT) and 5 competing strategies proposed. (2E) Telaprevir response-guided therapy (TVR-RGT): all patients started triple therapy with PEG-IFN, ribavirin and telaprevir (PR + TVR). Patients who achieved an extended virologic response (eRVR), defined as undetectable HCV RNA at Weeks 4 and 12, received the T12/PR24 regimen, while patients who failed to achieve eRVR (no eRVR) received the T12/PR48 regimen.
HEP_25734_sm_SuppFig2F.tif28KSupporting Information Appendix Figure 2. Dual therapy (DT) and 5 competing strategies proposed. (2F) Telaprevir IL28B genotype-guided strategy (TVR-IL28B): IL28B C/C patients were treated with dual therapy (DT), while IL28B C/T or T/T patients received telaprevir response-guided therapy. IL28B C/C patients treated with DT, and who did not achieved SVR, were retreated with 12 weeks of TVR in combination with PR, followed by 35 weeks of PR according to REALIZE RCT (22).
HEP_25734_sm_SuppInfo.doc39KSupporting Information

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.